This activity has been extended to May 31, 2019. PLEASE NOTE BEFORE YOU REGISTER THIS COURSE:
This activity will be updated in Spring of 2019 and the NEW VERSION will be available in the AANP CE Center.
Reference Number: 16122474
Release Date: January 17, 2017
To qualify, NPs and PAs must:
• Be aware of any state law regarding the treatment of addiction/OUD
• Be licensed under state law to prescribe schedule III, IV, or V medications for pain
• Complete not less than 24 hours of appropriate education through a qualified provider
• Through other training or experience, demonstrate the ability to treat and manage OUD
• If required by state law, be supervised or work in collaboration with a qualified* physician to prescribe medications for the treatment of OUD
*NOTE: CARA also defers to state law regarding whether an NP or PA works with a physician through a supervisory or collaborative relationship and, where this applies, the physician must also be qualified to prescribe buprenorphine.
Completing this Activity
Once you have REGISTERED this course in the AANP CE Center, under Download Materials, review the instructions provided for completing this activity on the Partner site.
Participants must complete, in full, both parts of this educational requirement to be waivered (see below) - both are included in this 24-hour CE course.
8-Hour Training: Part I: The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements
16-Hour Training: Part II: NP/PA 16-Hour Waiver Training
Learners will be directed to a partner site for content, and re-directed back to the AANP CE Center to complete the requirements for CE and obtain the CE Certificate.Learners must log on in the Partner site and Register this course on their site to continue.
A participation code will be provided at the end of the CE activity's content. See Instructions for details.
Completions are reported weekly to the Center for Substance Abuse Treatment (CSAT). Learners must apply for the waiver to prescribe buprenorphine to their patients with opioid use disorders.
NOTE: CARA also defers to state law regarding whether an NP or PA works with a physician through a supervisory or collaborative relationship and, where this applies, the physician must also be waivered to prescribe buprenorphine.
This CE activity provides two training sessions that must be completed to fulfill the 24-hour continuing education training requirements outlined in the Comprehensive Addiction and Recovery Act (CARA). Participants must complete both activities to qualify for the waiver application. Those who complete this educational activity must allow a week for their information to be reported and then will be able to apply for the waiver to prescribe buprenorphine for patients with opioid addiction.
ASAM, AANP and AAPA have formed a collaborative to provide the 24-hour waiver training for nurse practitioners and physician assistants. Educational content has been identified and/or created to satisfy the 24-hour requirement as described in the Comprehensive Addiction and Recovery Act (CARA).
8-hour Activity Overview: Part I: The ASAM Treatment of Opioid Use Disorder Course: Includes Waiver Qualifying Requirements - will ensure that participants are exposed to the highest quality, evidence-based practices when using buprenorphine to treat opioid use disorders.
16-hour Activity Overview: Part II: NP/PA 16-Hour Waiver Training - The 16-hour product developed includes all additional education required by the Comprehensive Addiction and Recovery Act (CARA) for nurse practitioners to successfully apply for a waiver to prescribe buprenorphine for office-based treatment of opioid use disorders.
At the completion of this presentation Learners will be able to:
Apply for a waiver to prescribe buprenorphine to their patients with opioid use disorders
Identify and assess patients who are appropriate for treatment with medications
Have specific knowledge concerning the use of medications to manage patients with addiction involving opioid use
Discuss the psychiatric and medical co-morbidities associated with opioid addiction
Content Developers and Speakers
Daniel P. Alford, MD, MPH, FACP, DFASAM
Sarah Bagley, MD
Jeffrey Baxter, MD
Adam Bisaga, MD
Timothy K. Brennan, MD, MPH
Theordore Cicero, PhD
Captain Jennifer Fan, PharmD, JD
James W. Finch, MD, DFASAM
Debra Houry, MD, MPH
Brian Hurley, MD, MBA, DFASAM
Magaret A. Jarvis, MD, DFASAM
Karol Kaltenbach, PhD
Kyle Kampman, MD
Colleen Labelle, BSN, RN-BC, CARN
Lorenzo Leggio, MD, PhD, MSc
Sharon Levy, MD, MPH
Raye Z. Litten, PhD,
Paula Lum, MD, MPH, FASAM
Barbara Mason, PhD
David Mee-Lee, MD, FASAM
Yngvild K. Olsen, MD, MPH, FASAM
Ricardo Restrepo, MD, MPH,
Richard N. Rosenthal, MD, FASAM
Kelley Saia, MD
Edwin A. Salsitz, MD, DFASAM
Andrew Saxon, MD, FASAM
Mark Sullivan, MD, PhD,
Frank J. Vocci, PhD,
R. Corey Waller, MD, MS, DFASAM,
Alexander Y. Walley, MD, MSc, FASAM,
Timothy J. Weigand, MD, DABAM, FACMT, FAACT
Tricia Wright, MD, MS, FACOG, FASAM
Tricia E. Wright, MD, MS, FACOD, FASAM
Stephen A. Wyatt, DO, FASAM
This activity was planned in accordance with AANP Accreditation Standards and Policies in collaboration with ASAM, and AAPA to provide the 24 hours of required education. Planner, faculty, and all other relevant disclosures are listed on the ASAM website.
The collaborative of ASAM, AANP and AAPA identified and reviewed this content to provide the NP/PA training required by CARA. The NP/PA 24-Hour Waiver Training is available for free through 2018 in part by an unrestricted educational grant from Indivior.
This educational activity may contain opinions of the speakers from their personal experience. The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
To complete the CE for this activity, successfully complete all content and posttests on the partner site, and then submit the online program evaluation in the AANP CE Center.
For questions about this online CE activity, or more information concerning the AANP CE Center, contact the AANP CE Center Manager at CECenter@aanp.org.
24 Contact Hour(s) of CE, 18 of which may be applied towards Pharmacology
Additional CE activities of interest
(OnDemand (MP4/MP3)) Managing Aberrant Drug Taking Behaviors and Opioid Use Disorder
(OnDemand (MP4/MP3)) Preventing Opioid Emergencies: Naloxone Prescribing in Chronic Pain
(OnDemand (SCORM)) Safe Opioid Prescribing Series: How to Safely and Effectively Treat Pain in Primary Care
(OnDemand (MP4/MP3)) Using National Pain Management Standards to Document Safe Practice: A Regulatory Perspective
(Publication ) Acute Pain Management in Opioid Tolerant Individuals
(OnDemand (MP4/MP3)) Pain Management in Individuals with Serious Illness and Co-Morbid Substance Use Disorders
(OnDemand (External)) NP/PA 16-Hour Buprenorphine Waiver Training: Part II Only
(OnDemand (MP4/MP3)) Current Issues with Opioid Overprescribing and Misuse